论文部分内容阅读
目的 探讨苦参素与阿昔洛韦治疗慢性乙型肝炎的临床疗效及不良反应。方法 选择慢性乙型肝炎患者83例,随机分成治疗组42例,给予苦参素60 0mg d-1,im ,疗程为3个月;对照组41例,给予阿昔洛韦15mg kg-1 d-1,缓慢ivgtt ,1个月后改为阿昔洛韦片10 0mg d-1,分5次po ,连用2个月,同时两组均配合使用常规护肝药物。疗效结束时,观察两组患者临床症状体征,肝功能及乙肝病毒血清学标志(HBVM )的变化。结果 治疗组在临床症状,体征改善以及肝功能的改善率明显高于对照组(P <0 . 0 5 ) ,两组HBeAg的阴转率分别为5 0 0 %和2 1. 9% ,两组HBV -DNA的阴转率分别为5 2 . 4%和2 4 .4% ,治疗组的疗效明显优于对照组(P <0 . 0 5 ) ,未见明显不良反应。结论 苦参素治疗慢性乙型肝炎疗效确切,价格低廉,无毒副作用,可在临床推广使用。
Objective To investigate the clinical efficacy and adverse reactions of oxymatrine and acyclovir in the treatment of chronic hepatitis B. Methods Eighty-three patients with chronic hepatitis B were randomly divided into treatment group (n = 42), matrine (60 mg · d-1, im) for 3 months, and control group (n = 41) -1, slow ivgtt, 1 month later to acyclovir film 10 0mg d-1, 5 po, once every 2 months, while the two groups are used in conjunction with conventional hepatoprotective drugs. At the end of the curative effect, clinical symptoms and signs, liver function and hepatitis B virus serological markers (HBVM) were observed. Results The improvement rates of clinical symptoms, signs and liver function in the treatment group were significantly higher than those in the control group (P <0.05). The negative conversion rates of HBeAg in the two groups were respectively 500% and 21.9% Group HBV-DNA negative conversion rates were 52.4% and 24.4%, the treatment group was significantly better than the control group (P <0. 05), no significant adverse reactions. Conclusion Oxymatrine treatment of chronic hepatitis B has the exact effect, low price, no toxic and side effects, and can be widely used in clinic.